New predicted dual CDK-2/CDK-1 inhibitors from Aspergillus unguis isolate SP51-EGY with relative selectivity for colorectal cancer cells: a computational and experimental approach.

Ahmed A El-Rashedy, Amal Mosad Ibrahim, Mohamed S Abdel-Aziz, Walid Fayad, Faten K Abd El-Hady

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Evaluating the anti-gut dysbiotic potential of bioactive primary metabolites derivatives fromFrontiers in nutrition · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ahmed A El-RashedyChemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, 33 El Buhouth St., Dokki-Giza, 12622, Egypt.

Amal Mosad IbrahimChemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, 33 El Buhouth St., Dokki-Giza, 12622, Egypt.

Mohamed S Abdel-AzizDepartment of Microbial Chemistry, National Research Centre, Giza, 12622, Egypt.

Walid FayadDrug Bioassay-Cell Culture Laboratory, Pharmacognosy Department, National Research Centre, Giza, 12622, Egypt.

Faten K Abd El-HadyChemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, 33 El Buhouth St., Dokki-Giza, 12622, Egypt. fk.abdel-hady@nrc.sci.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is one of the deadliest cancers in the world. The main problem with cancer treatments is that they need to protect healthy cells. Cyclin-dependent kinases (CDKs), especially CDK-2 and CDK-1, are essential for regulating the cell cycle, cell growth, and tumor genesis. Their dysregulation is frequently detected in colorectal cancer, resulting in uncontrolled cell division and resistance to apoptosis, making them attractive targets for anticancer therapy. The fungal "Aspergillus unguis isolate SP51-EGY" "Sh cell" (shake mycelia) extract had the most significant cytotoxic action against HCT116 cancer cells (IC

Indexed as

Antineoplastic AgentsAspergillusCDC2 Protein KinaseColorectal NeoplasmsCyclin-Dependent Kinase 2Protein Kinase InhibitorsCell Line, TumorHCT116 CellsHumansMolecular Docking SimulationAntineoplastic AgentsCDC2 Protein KinaseCDK1 protein, humanCDK2 protein, humanCyclin-Dependent Kinase 2Protein Kinase InhibitorsAspergillus unguis isolate SP51-EGYCDK-2 and CDK-1 inhibitorsHCT116 cancerIn silico study

Identifiers

PMID41965404

DOI10.1038/s41598-026-41120-2

PMCPMC13076678

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.